Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 43.54% |
| 2 | Technology | 19.7% |
| 3 | Financials | 7.47% |
| 4 | Consumer Discretionary | 6.7% |
| 5 | Communication Services | 6.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
4951
Kimbell Royalty Partners
KRP
$1.47B
| $1.55K | ﹤0.01% |
132
+69
| +110% | +$884 |
2023 Q2
10 quarters
|
|
4952
PUT
Rocket Companies
RKT
$33.1B
| $1.53K | ﹤0.01% |
79
-600
| -88% | -$10.7K |
2025 Q2
2 quarters
|
|
4953
Comstock
LODE
$173M
| $1.5K | ﹤0.01% |
+399
| New | +$1.36K |
2025 Q4
0 quarters
|
|
4954
Innovator Premium Income 15 Buffer ETF January
LJAN
$12.3M
| $1.43K | ﹤0.01% |
58
-269
| -82% | -$6.64K |
2025 Q2
2 quarters
|
|
4955
CrossAmerica Partners
CAPL
$831M
| $1.4K | ﹤0.01% |
68
+16
| +31% | +$329 |
2025 Q2
2 quarters
|
|
|
ORIO
4956
Orion Digital Corp
ORIO
$24.8M
| $1.39K | ﹤0.01% |
1,300
+700
| +117% | +$996 |
2025 Q3
1 quarter
|
|
|
RPTX
4957
DELISTED
Repare Therapeutics
RPTX
| $1.38K | ﹤0.01% |
530
| – | – |
2023 Q2
10 quarters
|
|
4958
MDxHealth
MDXH
$54.5M
| $1.37K | ﹤0.01% |
384
-9,676
| -96% | -$38.2K |
2025 Q3
1 quarter
|
|
|
ZYXI
4959
DELISTED
Zynex
ZYXI
| $1.34K | ﹤0.01% |
10,652
| – | – |
2022 Q1
15 quarters
|
|
|
SZZLU
4960
Sizzle Acquisition Corp II Unit
SZZLU
| $1.29K | ﹤0.01% |
126
| – | – |
2025 Q2
2 quarters
|
|
4961
Riskified
RSKD
$1.04B
| $1.29K | ﹤0.01% |
259
| – | – |
2022 Q2
14 quarters
|
|
4962
KLX Energy Services
KLXE
$29.5M
| $1.26K | ﹤0.01% |
667
| – | – |
2023 Q1
11 quarters
|
|
4963
Inovio Pharmaceuticals
INO
$120M
| $1.26K | ﹤0.01% |
722
+721
| +72,100% | +$1.59K |
2024 Q2
6 quarters
|
|
4964
Innovator US Equity Ultra Buffer ETF September
USEP
$239M
| $1.22K | ﹤0.01% |
+31
| New | +$1.21K |
2025 Q4
0 quarters
|
|
4965
FT Vest US Equity Enhance & Moderate Buffer ETF October
XOCT
$66.7M
| $1.17K | ﹤0.01% |
31
-5,419
| -99% | -$202K |
2024 Q3
5 quarters
|
|
4966
Lufax Holding
LU
$884M
| $1.15K | ﹤0.01% |
450
-135,993
| -100% | -$402K |
2022 Q1
15 quarters
|
|
4967
CALL
Biohaven
BHVN
$1.94B
| $1.13K | ﹤0.01% |
100
-420,800
| -100% | -$5.21M |
2025 Q3
1 quarter
|
|
4968
Innovator US Equity Accelerated ETF Quarterly
XDSQ
$69.8M
| $1.04K | ﹤0.01% |
25
-3,688
| -99% | -$150K |
2024 Q3
5 quarters
|
|
|
BNT
4969
Brookfield Wealth Solutions
BNT
$11B
| $965 | ﹤0.01% |
21
| – | – |
2024 Q3
5 quarters
|
|
4970
AllianzIM U.S. Equity Buffer20 May ETF
MAYW
$456M
| $906 | ﹤0.01% |
27
-13
| -33% | -$431 |
2025 Q3
1 quarter
|
|
4971
Ostin Technology Group
OST
| $839 | ﹤0.01% |
495
| – | – |
2025 Q2
2 quarters
|
|
4972
iShares MSCI USA Quality Factor ETF
QUAL
$48.3B
| $794 | ﹤0.01% |
4
-70
| -95% | -$13.8K |
2025 Q1
3 quarters
|
|
4973
60 Degrees Pharmaceuticals
SXTP
$4.89M
| $769 | ﹤0.01% |
+378
| New | +$1.75K |
2025 Q4
0 quarters
|
|
|
SDM
4974
DELISTED
Smart Digital Group
SDM
| $649 | ﹤0.01% |
351
| – | – |
2025 Q3
1 quarter
|
|
|
ENGS
4975
Energys Group
ENGS
$136M
| $604 | ﹤0.01% |
+709
| New | +$2.86K |
2025 Q4
0 quarters
|
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $23.5B in Q4 2025, closing 641 positions and reducing 1,714 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 44% of assets, down from 44% a quarter earlier, followed by Technology and Financials.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.